Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Pattern of Failure and Feasibility of Consolidative Stereotactic Radiotherapy in Third-generation EGFR-TKI-treated Metastatic EGFR-mutant Non-small Cell Lung Cancer: A Prospective, Observational Study
Sponsor: Fudan University
A observational or N/A phase clinical study on NSCLC (Advanced Non-small Cell Lung Cancer) and Third-generation TKI, this trial is completed. The trial is conducted by Fudan University and has accumulated 4 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
May 4, 2026 — Present [daily]
Completed
-
May 2025 — May 2026 [monthly]
Completed
-
Nov 2024 — May 2025 [monthly]
Completed
-
Oct 2024 — Nov 2024 [monthly]
Completed
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment, the characteristics of the distribution of lesions when the best response is achieved, the feasibility of SRT when the best response is achieved, and the phenotype of disease progression after EGFR-TKI resistance. In summary, this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI, which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC.
Contact Information
- Fudan University
- Shanghai Chest Hospital
- Wuhan TongJi Hospital
For direct contact, visit the study record on ClinicalTrials.gov .